



Press Release

April 11, 2022

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer, President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Executive Officer, CFO
Joseph Francis Meyer
(TEL. 03-6214-3600)

Ranked in the Financial Times "High-Growth Companies Asia-Pacific 2022" for the third consecutive year

GNI Group Ltd. is pleased to announce that the Group is ranked for the third consecutive year in the "High-Growth Companies Asia-Pacific 2022" FT Special Report published on April 7, 2022. The Group is ranked 219th this year.

The list, compiled by the Financial Times (U.K.) and Statista (Germany), is comprised of the 500 companies in 13 territories within the Asia-Pacific region that have accomplished the highest compound annual growth rate in revenues between 2017 and 2020.

For more information, please refer to the following URL:
<https://www.ft.com/high-growth-asia-pacific-ranking-2022>

About GNI Group, Inc.

GNI Group is a global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China.

For more information, please visit our website at <https://www.gnipharma.com/>